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primary	 brain	 tumors.	 Thus,	 the	management	 of	 anticoagulant	 therapy	 for	VTE	 is	
challenging and controversial in these patients. We performed a meta-analysis to 
clarify	the	risk	of	ICH	in	glioma	patients	treated	with	anticoagulant	therapy	for	VTE	
compared	to	glioma	patients	without	VTE.
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1  | INTRODUC TION
Venous	thromboembolism	(VTE)	is	common	in	malignant	glioma	pa-






tients,	 the	management	of	anticoagulant	 therapy	 for	both	preven-
tion	and	treatment	of	VTE	is	complex	and	challenging	(Jo,	Schiff,	&	
Perry,	2014;	Perry	et	al.,	2010;	Porfidia,	Morretti,	&	Landolfi,	2014;	
Senders	et	 al.,	2018).	Few	data	are	available	on	 the	 risk	of	 ICH	 in	
malignant glioma patients who use anticoagulants for the treatment 
of	VTE.







Data reporting in this review are consistent with the Preferred 
Reporting	 Items	for	Systematic	Reviews	and	Meta-Analyses	state-
ment	(Moher,	Liberati,	Tetzlaff,	&	Altman,	2009).	The	review	ques-




restrictions. The search strategy used a combination of the following 
keywords:	 glioma,	 glioblastoma,	 oligodendroglioma,	 astrocytoma,	
oligoastrocytoma,	 anticoagulant,	 heparin,	 low-molecular-weight	
heparin,	vitamin	k	antagonist,	direct	oral	anticoagulant	(DOAC),	and	
new oral anticoagulant.
The inclusion criteria were as follows: case–control or cohort 
studies or randomized trials that enrolled patients with primary ma-




available information on the occurrence of intracranial bleeding in 
both groups.
The list of potentially eligible studies was reviewed by two inde-
pendent	reviewers	(A.P.	and	M.G.).	The	reference	lists	of	retrieved	
articles were also scrutinized to identify other publications of interest 
that	were	missed	in	the	first	search	(forward	search).	Disagreements	
between reviewers were resolved by consensus.




The	primary	analysis	was	 conducted	on	 the	 rate	of	 ICH	 in	pa-
tients affected by brain cancers receiving full-dose anticoagulants 
for	VTE	compared	with	those	not	receiving	anticoagulation.








Institutional	 review	 board	 approval	 was	 not	 required	 in	 our	
Institution for a systematic review and a meta-analysis.
2.1 | Statistical analysis
Data of the study populations were reported as per individual stud-
ies.	 The	 number	 of	 patients	who	 experienced	 and	did	 not	 experi-
ence	ICH	was	extracted	both	in	the	anticoagulant	and	in	the	control	
group.	A	random	effect	model	using	inverse	variance	weighting	was	
used to summarize the data. The heterogeneity of pooled data was 
estimated by calculating the Q and I2	statistics,	and	it	was	regarded	







purpose of the study. The remaining 22 studies were reviewed in 
detail.	 According	 to	 the	 PICO	 criteria,	 15	 studies	 were	 excluded.	
In	 particular,	 eight	 studies	were	 excluded	 because	 no	 comparison	
group	was	available	 (Altschuler,	Moosa,	Selker,	&	Vertosick,	1990;	
Carney	et	 al.,	 2019;	Chaichana	et	 al.,	 2013;	Nghiemphu,	Green,	&	
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3.2 | Study characteristics










with a primary malignant brain cancer receiving therapeutic antico-







tistical analysis of bias was performed.
4  | DISCUSSION
The results of this meta-analysis show a significant 3.66-fold in-




anticoagulant	 therapy	 for	VTE	 is	difficult.	Subjects	with	primary	
malignant	 brain	 tumors	 who	 develop	 VTE	 are	 among	 those	 for	
whom the assessment of the risk–benefit ratio of anticoagulation 
is	 particularly	 complex,	 given	 the	 lack	 of	 solid	 scientific	 data	 to	
drive	 the	 best	 medical	 management.	 A	 previous	 meta-analysis,	
























Pubmed, Scopus, Embase databases  
and additional records identified 
through forward search
368 records screened 
346 discared
(duplicates or excluded after 
title and abstract                                      
evaluation
22 full text-articles 
assessed for elegibility
7 studies included                                               
in the final analysis
15 full-text excluded:
- 8 due to the absence of a comparison group 
- 4 for a different outcome
- 3 for a different intervention 
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(Zwicker,	 Karp	 Leaf,	 &	 Carrier,	 2016).	 After	 this	 meta-analysis,	
other two studies have been published and are included in the 
present meta-analysis. Ours is the first meta-analysis that is spe-






the	OR	 for	 ICH	 in	 treated	 versus	 untreated	 patients	 was	 7.5.	 On	
the	other	hand,	 in	the	study	by	Mantia	and	coll.,	 the	authors	have	
distinguished	between	ICHs	of	different	severity,	from	trace	radio-




orrhages	 that	 were	more	 than	 10	ml	 in	 volume,	 required	 surgical	
intervention,	 or	were	 associated	with	 clinical	 symptoms	were	 de-
fined	as	major.	When	all	hemorrhages	were	considered	as	a	whole,	
their	1-year	incidence	was	28.1%	in	subjects	receiving	anticoagulant	
therapy	 and	13.6%	 in	 controls.	When	only	measurable	 ICHs	were	
considered,	their	1-year	incidence	was	18.8%	in	the	anticoagulation	
group	and	7.8%	in	the	control	group.	Finally,	when	only	major	ICHs	




Ruff	and	Posner	(1983) ★★★ / ★
Choucair	et	al.	(1987) ★★★ / ★
Pan	et	al.	(2009) ★★★ / ★★
Norden	et	al.	(2012) ★★★ / ★




Mantia	et	al.	(2017) ★★★ ★★ ★★★
Al	Megren	et	al.	(2017) ★★★ ★★ ★★★
F I G U R E  2  Forest	plot	and	pooled	estimate	of	odds	ratio	(OR)	of	intracranial	hemorrhage	in	glioma	patients	receiving	therapeutic	
anticoagulation	for	VTE.	CI,	confidence	interval;	VTE,	venous	thromboembolism
F I G U R E  3  Funnel	plot	of	standard	error	(SE)	of	studies	included	
in	the	meta-analysis.	OR,	odds	ratio
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were	 taken	 into	 consideration,	 the	 1-year	 incidence	was	 14.7%	 in	
subjects	receiving	anticoagulation	versus	2.5%	in	subjects	that	were	
not	on	anticoagulant	therapy	(HR	3.37).	The	study	of	Pan	and	coll.	
included	 subjects	who	have	had	 recent	 surgery	 (Pan	et	 al.,	 2009).	
Of	146	subjects,	41	(28%)	developed	VTE,	25	(17%)	where	treated	
with	full-dose	anticoagulant	and	3	(2%)	developed	ICH.	Norden	and	
coll. studied brain cancer patients treated with bevacizumab and 
receiving	anticoagulant	 therapy	 for	VTE	 (Norden	et	al.,	2012)	ver-
sus	a	control	group	of	non-VTE	patients	treated	with	bevacizumab	
alone.	Bevacizumab	 is	a	humanized	monoclonal	antibody	direct	 to	
vascular endothelial growth factor approved for the treatment of 








dian survival was similar among patients receiving and not receiv-
ing	 anticoagulation,	 although	 the	 diagnosis	 of	 ICH	while	 receiving	







about	 60%	of	 patients	with	 brain	 tumors	 treated	with	 IVC	 filter	
developed	complications	related	to	the	filter,	including	a	high	rate	
of	pulmonary	embolism	and	 thrombosis	of	 the	 filter	 (45%)	 (Levin	
et	 al.,	 1993).	 In	 a	 recent	 study,	 in	 patients	with	 glioma	 and	VTE	
who	underwent	placement	of	 an	 IVC	 filter,	 the	 rate	of	 recurrent	
VTE	was	30%	with	an	additional	5%	of	mechanical	complications	
regardless of the presence or absence of anticoagulant treatment 
(Edwin	et	al.,	2016).	Thus,	the	use	of	IVC	filters	should	be	carefully	
evaluated	 for	 each	 individual	 patient,	 always	 taking	 into	 consid-
eration	 that,	 for	 primary	 brain	 tumors,	 the	 American	 Society	 of	
Clinical Oncology recommends anticoagulation and does not sup-
port	 the	 routine	 use	 of	 IVC	 filter	 in	 glioma	patient	who	develop	
VTE	7	(Lyman	et	al.,	2013).










subjects with malignant brain tumors.
This	study	has	some	limitations.	First,	it	is	based	on	studies	that	











In	 summary,	 our	 meta-analysis	 suggests	 that	 anticoagulation	 in-
creases	 the	 risk	 of	 ICH	 in	 subjects	 with	 malignant	 brain	 tumors	
and	VTE,	although	 in	some	studies	 ICH	does	not	 influence	overall	
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